Norvir (Ritonavir)

Ritonavir, the active ingredient in Norvir, is a protease inhibitor presented as an oral dosage form for oral use. It treats HIV-1 infection in combination with other antiretroviral agents. It is used as part of highly active antiretroviral therapy (HAART) to suppress viral replication and improve immune function.

GNH USA supplies Norvir as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, transplant centres and oncology centres worldwide, adhering to EU quality standards and providing regulatory documentation, including detailed batch release certificates and stability data.

Ritonavir is a protease inhibitor used in the management of HIV-1 infection and related therapeutic strategies.

- HIV-1 infection: used in combination with other antiretroviral agents to achieve viral suppression. - Protease inhibitor boosting: co‑administered to increase plasma concentrations of other protease inhibitors. - Treatment‑experienced HIV patients: incorporated into regimens for individuals with prior antiretroviral exposure to enhance efficacy.

Ritonavir may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools occurring intermittently. - Fatigue: general feeling of tiredness. - Headache: mild to moderate cranial pain. - Rash: skin erythema or pruritus. - Taste alteration: dysgeusia or metallic taste.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis. - Pancreatitis: inflammation of the pancreas with abdominal pain. - QT interval prolongation: cardiac conduction abnormalities. - Severe allergic reactions: anaphylaxis or Stevens‑Johnson syndrome. - Hyperglycemia: significant rise in blood glucose levels. - Lipodystrophy: abnormal fat redistribution.

Before initiating ritonavir therapy, clinicians should consider several safety measures.

- Liver monitoring: assess hepatic function regularly due to risk of hepatotoxicity. - Lipid assessment: evaluate cholesterol and triglyceride levels as dyslipidemia may occur. - Glucose surveillance: monitor blood glucose, especially in diabetic patients. - Hypersensitivity: avoid use in individuals with known ritonavir allergy. - Drug‑specific dosing: adjust concomitant protease inhibitor doses when required. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Ritonavir interacts with many medications through CYP3A4 inhibition, requiring careful management.

Major Interactions (Avoid): - Simvastatin: risk of severe myopathy and rhabdomyolysis. - Cisapride: can cause life‑threatening cardiac arrhythmias. - Ergot alkaloids: may precipitate ergotism with vasospasm.

Moderate Interactions (Monitor Closely): - Atorvastatin: may increase statin exposure; dose adjustment recommended. - Midazolam: enhanced sedation; consider dose reduction. - Rifampicin: strong CYP3A4 inducer that reduces ritonavir levels; avoid co‑administration.